Fact Sheets - Released in 2015
- Much progress has been made in research and development of new drugs for TB over the last decade.
- There are currently eight new or repurposed drugs in Phase I, Phase II or Phase III trials for the treatment of drug-susceptible, drug-resistant TB or latent TB infection.
- Two novel drugs, bedaquiline and delamanid, have been approved by stringent regulatory authorities under accelerated or conditional approval procedures for the treatment of MDR-TB as part of combination therapy for adults with pulmonary TB when other alternatives are not available.
Downloads
Download Fact Sheet(672.84 KB)
Organizations
- World Health Organization (WHO)